JP2015520378A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520378A5
JP2015520378A5 JP2015514216A JP2015514216A JP2015520378A5 JP 2015520378 A5 JP2015520378 A5 JP 2015520378A5 JP 2015514216 A JP2015514216 A JP 2015514216A JP 2015514216 A JP2015514216 A JP 2015514216A JP 2015520378 A5 JP2015520378 A5 JP 2015520378A5
Authority
JP
Japan
Prior art keywords
cell
therapy
central memory
sample
cd45ro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015514216A
Other languages
English (en)
Japanese (ja)
Other versions
JP6312332B2 (ja
JP2015520378A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/042627 external-priority patent/WO2013177505A1/en
Publication of JP2015520378A publication Critical patent/JP2015520378A/ja
Publication of JP2015520378A5 publication Critical patent/JP2015520378A5/ja
Application granted granted Critical
Publication of JP6312332B2 publication Critical patent/JP6312332B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015514216A 2012-05-24 2013-05-24 糖尿病バイオマーカ Active JP6312332B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261651144P 2012-05-24 2012-05-24
US61/651,144 2012-05-24
PCT/US2013/042627 WO2013177505A1 (en) 2012-05-24 2013-05-24 Diabetes biomarkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018027381A Division JP6761827B2 (ja) 2012-05-24 2018-02-19 糖尿病バイオマーカ

Publications (3)

Publication Number Publication Date
JP2015520378A JP2015520378A (ja) 2015-07-16
JP2015520378A5 true JP2015520378A5 (enExample) 2016-11-24
JP6312332B2 JP6312332B2 (ja) 2018-04-18

Family

ID=49621783

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2015514216A Active JP6312332B2 (ja) 2012-05-24 2013-05-24 糖尿病バイオマーカ
JP2018027381A Expired - Fee Related JP6761827B2 (ja) 2012-05-24 2018-02-19 糖尿病バイオマーカ
JP2020150183A Pending JP2021001899A (ja) 2012-05-24 2020-09-07 糖尿病バイオマーカ
JP2022175993A Pending JP2023011814A (ja) 2012-05-24 2022-11-02 糖尿病バイオマーカ
JP2024120652A Pending JP2024150702A (ja) 2012-05-24 2024-07-25 糖尿病バイオマーカ

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018027381A Expired - Fee Related JP6761827B2 (ja) 2012-05-24 2018-02-19 糖尿病バイオマーカ
JP2020150183A Pending JP2021001899A (ja) 2012-05-24 2020-09-07 糖尿病バイオマーカ
JP2022175993A Pending JP2023011814A (ja) 2012-05-24 2022-11-02 糖尿病バイオマーカ
JP2024120652A Pending JP2024150702A (ja) 2012-05-24 2024-07-25 糖尿病バイオマーカ

Country Status (13)

Country Link
US (5) US20130316375A1 (enExample)
EP (2) EP3767295A1 (enExample)
JP (5) JP6312332B2 (enExample)
KR (1) KR102172285B1 (enExample)
CN (1) CN104520707B (enExample)
AU (4) AU2013266145A1 (enExample)
CA (1) CA2874507A1 (enExample)
DK (1) DK2856149T3 (enExample)
ES (1) ES2810227T3 (enExample)
IN (1) IN2014DN10259A (enExample)
MX (1) MX357169B (enExample)
WO (1) WO2013177505A1 (enExample)
ZA (1) ZA201409006B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers
CN113138279A (zh) 2012-06-27 2021-07-20 法姆制药有限责任公司 融合蛋白组合物的应用
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
WO2016103390A1 (ja) * 2014-12-25 2016-06-30 株式会社日立製作所 インスリン分泌能分析装置、当該装置を備えるインスリン分泌能分析システム及びインスリン分泌能分析方法
CN105567851A (zh) * 2016-02-29 2016-05-11 北京泱深生物信息技术有限公司 一种与糖尿病相关的分子标志物
EP3433612B1 (en) * 2016-03-22 2024-10-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and kits of assessing status, risk or prognosis of type 1 diabetes
CA3184157A1 (en) 2020-06-26 2021-12-30 Phaim Pharma Ltd Psoriasis and other autoimmune diseases antigen immune modulator (aim) therapeutic platform
US20240277768A1 (en) 2021-06-17 2024-08-22 Tihamer Orban Individualized Cell Therapy Using Patient-Derived Antigen-Specific Regulatory T Cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1930415A4 (en) * 2005-09-30 2009-05-13 Univ Kyoto DEVELOPMENT OF A SCREENING METHOD FOR A CONNECTABLE COMPOUND FOR IMPROVING THE PRODUCTION OF A REGULATORY T-CELL AND METHOD FOR THE PRODUCTION OF A REGULATORY T-CELL USING AN IMMUNOSUPPRESSIVE MAKROLIDANTIBIOTIC
US9176122B2 (en) * 2008-03-24 2015-11-03 University Of South Florida Biomarkers for predicting response to immunosuppressive therapy
US20100080784A1 (en) * 2008-09-12 2010-04-01 Torrey Pines Institute For Molecular Studies Methods for treating cachexia and lymphopenia
US20130316375A1 (en) * 2012-05-24 2013-11-28 Orban Biotech Llc Diabetes biomarkers

Similar Documents

Publication Publication Date Title
JP2015520378A5 (enExample)
Lo et al. Biomarkers for kidney transplant rejection
Lu et al. NanoVelcro Chip for CTC enumeration in prostate cancer patients
Piroird et al. The Myeloid U937 Skin Sensitization Test (U-SENS) addresses the activation of dendritic cell event in the adverse outcome pathway for skin sensitization
Qian et al. Analysis and biomedical applications of functional cargo in extracellular vesicles
AR060121A1 (es) Medio y metodo para predecir la diabetes
WO2010002911A3 (en) Methods and materials for monitoring myeloma using quantitative mass spetrometry
EA200971114A1 (ru) Определение антигенов, расположенных на эритроцитах, и антиэритроцитарных антител
MY162697A (en) Methods, devices and kits for detecting or monitoring acute kidney injury
Fu et al. Liquid biopsy technologies for hematological diseases
MX2007014815A (es) Metodos de inmunoanalisis mejorados.
JP2013518244A5 (enExample)
Ayers et al. Procoagulant and platelet-derived microvesicle absolute counts determined by flow cytometry correlates with a measurement of their functional capacity
WO2012151105A3 (en) Basophil analysis system and method
CA2855971C (en) Methods for detecting human papillomavirus and providing prognosis for head and neck squamous cell carcinoma
AR088108A1 (es) METODO PARA DETECTAR ANTICUERPOS ESPECIFICOS Ab EN UNA MUESTRA BIOLOGICA
JP2014533372A5 (enExample)
JP2017528715A5 (enExample)
RU2019104870A (ru) Комбинированный тест на наличие колоректального рака
JP2019082446A5 (enExample)
MX2020009705A (es) Metodos para la deteccion del riesgo de enfermedad renal cronica en un sujeto y metodo implementado por computadora.
Adamo et al. Lymphopenia-induced T cell proliferation is a hallmark of severe COVID-19
JP2014512014A5 (enExample)
JP2011528797A5 (enExample)
JP2011518338A5 (enExample)